Saltar al contenido
Merck

[Cortisone-resistant bronchial asthma].

Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna (1996-07-01)
A Matucci, O Rossi, M Ricci
RESUMEN

There is general agreement on the inflammatory pathogenesis of bronchial asthma: an accumulation of activated eosinophils, degranulated mast cells, T lymphocytes and in very severe forms, granulocytes has constantly been found in the bronchial mucosa. In allergic bronchial asthma, inflammation seems to be orchestrated predominantly by a subset of T lymphocytes, with a phenotype similar to the Th2 subset able to produce IL-4 and IL-5. Although corticosteroids are the most potent therapeutic agents used for this disease, their anti-inflammatory effect differs from patient to patient. Some criteria which can be used to define steroid-resistant bronchial asthma are listed here. This review analyzes various molecular alterations responsible for the deficient response to corticosteroid treatment observed in steroid-resistant bronchial asthmatic subjects. New knowledge on the mechanism of steroid resistance may have important implications for the treatment of chronic asthma and other diseases.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Cortisone, ≥95%